摘要
目的探讨CT导引下植入125I放射性密封籽源治疗中晚期肺癌的临床应用价值并进行随访评价。方法回顾分析72例失去手术机会的中晚期肺癌,运用治疗计划系统(TPS)按处方剂量设计籽源分布,全部病例行经静脉化疗2￣6次。治疗后1,2,6个月及1年行CT随访评价。结果1个月后随访病灶缩小76处,无变化8处,增大28处;2个月后随访病灶缩小84处,无变化4处,增大24处;6个月后随访病灶缩小98处,无变化2处,增大12处;1年后随访病灶缩小60处,无变化0处,增大28处,6个月后失随访12例共24处。随访中,患者新发生转移40例。随访6个月时生存率为100%(72/72),随访1年时生存率为85.71%(60/70)。结论植入125I放射性密封籽源治疗中晚期肺癌,操作安全,并发症少,6个月时临床疗效达到最佳,可重复进行,是综合治疗措施中值得应用的方法之一。
Objective To discuss the clinical value and evaluate through callback about curing rnetaphase or terminal lung cancer by embedding ^125Ⅰ under CT guidance. Methods 72 cases of metaphase or terminal lung cancer without the chance of operation had been analysed. The distribution of particles had been designed through TPS according to the dosages of prescription. The evaluate through callback had been done after 1, 2, 6 months and 1 year. Results After 1 month, 76 foci had been reduced, 8 foci no change, 28 foci enlarged. After 2 months, 84 foci had been reduced, 4 foci no change, 24 foci enlarged. After 6 months, 98 foci had been reduced, 2 foci no change, 12 foci enlarged. After 1 year, 60 loci had been reduced, 0 foci no change, 28 foci enlarged. 40 new loci had been discovered during callback. The rate of the exist was 100 % after 6 months, 85.71% after 1 year. Conclusion It is safe and its complications were few in curing metaphase or terminal lung cancer by embedding ^125Ⅰ under CT guidance, the clinic effect is best after 6 months of curing. This way can be repeated, and it is one of the integration cure way and is worthy of using.
出处
《肿瘤研究与临床》
CAS
2006年第6期376-379,共4页
Cancer Research and Clinic
